These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1131 related articles for article (PubMed ID: 30467760)
1. Evaluation of direct oral anticoagulants for the treatment of cancer-associated thrombosis: an update. Franco-Moreno A; Cabezón-Gutiérrez L; Palka-Kotlowsa M; Villamayor-Delgado M; García-Navarro M J Thromb Thrombolysis; 2019 Apr; 47(3):409-419. PubMed ID: 30467760 [TBL] [Abstract][Full Text] [Related]
2. Single-center, retrospective evaluation of safety and efficacy of direct oral anticoagulants versus low-molecular-weight heparin and vitamin K antagonist in patients with cancer. Pritchard ER; Murillo JR; Putney D; Hobaugh EC J Oncol Pharm Pract; 2019 Jan; 25(1):52-59. PubMed ID: 28825375 [TBL] [Abstract][Full Text] [Related]
3. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism. Beyer-Westendorf J; Ageno W Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150 [TBL] [Abstract][Full Text] [Related]
4. Treatment of Venous Thromboembolism in Cancer. Historical Perspective and Evolving Role of the Direct Oral Anticoagulants. Carrier M; Soff G; Le Gal G Cancer Treat Res; 2019; 179():103-115. PubMed ID: 31317483 [TBL] [Abstract][Full Text] [Related]
5. A single center retrospective cohort study comparing low-molecular-weight heparins to direct oral anticoagulants for the treatment of venous thromboembolism in patients with cancer - A real world experience. Phelps MK; Wiczer TE; Erdeljac HP; Van Deusen KR; Porter K; Philips G; Wang TF J Oncol Pharm Pract; 2019 Jun; 25(4):793-800. PubMed ID: 29460705 [TBL] [Abstract][Full Text] [Related]
6. [The role of direct oral anticoagulants in the management of cancer-associated thrombosis in 2020]. Auditeau C; Talbot A; Blandinières A; Smadja DM; Gendron N Bull Cancer; 2020 May; 107(5):574-585. PubMed ID: 32252973 [TBL] [Abstract][Full Text] [Related]
7. Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study. Alzghari SK; Seago SE; Garza JE; Hashimie YF; Baty KA; Evans MF; Shaver C; Herrington JD J Oncol Pharm Pract; 2018 Oct; 24(7):494-500. PubMed ID: 28714376 [TBL] [Abstract][Full Text] [Related]
8. Venous thromboembolism and cancer: Current and future role of direct-acting oral anticoagulants. Vedovati MC; Giustozzi M; Becattini C Thromb Res; 2019 May; 177():33-41. PubMed ID: 30849513 [TBL] [Abstract][Full Text] [Related]
9. An update on the efficacy and safety of novel anticoagulants for cancer associated thrombosis. Cosmi B Expert Opin Pharmacother; 2021 Apr; 22(5):583-594. PubMed ID: 33243038 [No Abstract] [Full Text] [Related]
10. Using direct oral anticoagulants (DOACs) in cancer and other high-risk populations. van Es N; Büller HR Hematology Am Soc Hematol Educ Program; 2015; 2015():125-31. PubMed ID: 26637711 [TBL] [Abstract][Full Text] [Related]
11. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Raskob GE; van Es N; Segers A; Angchaisuksiri P; Oh D; Boda Z; Lyons RM; Meijer K; Gudz I; Weitz JI; Zhang G; Lanz H; Mercuri MF; Büller HR; Lancet Haematol; 2016 Aug; 3(8):e379-87. PubMed ID: 27476789 [TBL] [Abstract][Full Text] [Related]
12. Are direct oral anticoagulants an economically attractive alternative to low molecular weight heparins in lung cancer associated venous thromboembolism management? Howlett J; Benzenine E; Fagnoni P; Quantin C J Thromb Thrombolysis; 2020 Oct; 50(3):642-651. PubMed ID: 32020515 [TBL] [Abstract][Full Text] [Related]
13. Comparing Direct Oral Anticoagulants and Warfarin for Atrial Fibrillation, Venous Thromboembolism, and Mechanical Heart Valves. Marcy TR; Truong T; Rai A Consult Pharm; 2015 Nov; 30(11):644-56. PubMed ID: 26629800 [TBL] [Abstract][Full Text] [Related]
14. [Low-molecular-weight heparins for cancer-associated thromboembolism: What place in 2019?]. Debourdeau P; Cossou-Gbeto C; Takam-Sohwe T; Laroche JP Bull Cancer; 2020 Feb; 107(2):224-233. PubMed ID: 32005356 [TBL] [Abstract][Full Text] [Related]
15. The treatment of cancer-associated venous thromboembolism in the era of the novel oral anticoagulants. Prandoni P Expert Opin Pharmacother; 2015; 16(16):2391-4. PubMed ID: 26360919 [TBL] [Abstract][Full Text] [Related]
16. Low molecular weight heparin versus rivaroxaban in the treatment of venous thromboembolism in gastrointestinal malignancies. Choe HK; De Sancho MT; Kim SS; Dai T; Shah MA Blood Coagul Fibrinolysis; 2018 Mar; 29(2):227-230. PubMed ID: 29389673 [TBL] [Abstract][Full Text] [Related]
17. Use of the Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism. Riva N; Ageno W Hematol Oncol Clin North Am; 2016 Oct; 30(5):1035-51. PubMed ID: 27637306 [TBL] [Abstract][Full Text] [Related]
18. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses. Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628 [TBL] [Abstract][Full Text] [Related]
19. Treatment of cancer-associated thrombosis: The evolution of anticoagulant choice and clinical insights into practical management. Riess H; Verhamme P; Weitz JI; Young A; Bauersachs R; Beyer-Westendorf J; Crowther M; Maraveyas A Crit Rev Oncol Hematol; 2021 Jan; 157():103125. PubMed ID: 33254037 [TBL] [Abstract][Full Text] [Related]
20. New oral anticoagulants: comparative pharmacology with vitamin K antagonists. Scaglione F Clin Pharmacokinet; 2013 Feb; 52(2):69-82. PubMed ID: 23292752 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]